RxDoctor Payments Data

Jacqueline Denysiak, MD

Family Medicine · San Diego, CANPI 1902337827

Payments from drug & device makers

$15,045in general payments, 2019–2025

Across 460 payments — averaging $32.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AstraZeneca$2K
  • Gilead$1K
  • Johnson & Johnson$898
  • Novo Nordisk$895
  • plus $4K from 26 others

What the payments were for

  • Consulting fees$1,2008%
  • Travel & lodging$3612%
  • Food & beverage$13,48390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,045 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$21,517
Medicare patients
69
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$45,367
OzempicSemaglutide30$40,302
EliquisApixaban20$28,474
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$7,799
Atorvastatin Calcium222$2,647
Celecoxib60$2,340
Duloxetine Hcl66$2,283
Losartan Potassium169$2,033
Levothyroxine Sodium137$1,842
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,826
ValacyclovirValacyclovir Hcl13$1,526
Rosuvastatin Calcium73$1,441
Pregabalin26$1,353
Trazodone Hcl64$1,334
Metoprolol Succinate70$1,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$51$45,36740 claims
Novo NordiskOzempic$895$40,30230 claims
PfizerEliquis$111$28,47420 claims
AstraZenecaBreztri Aerosphere$1,970$7,79914 claims
AbbVieSynthroid$3,858$1,22719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →